|
1
|
Simpson PT, Reis-Filho JS and Lakhani SR:
Breast pathology: Beyond morphology. Semin Diagn Pathol. 27:91–96.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bevers TB, Anderson BO, Bonaccio E, Buys
S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE,
et al: NCCN clinical practice guidelinesin oncology: Breast cancer
screening and diagnosis. J Natl Compr Cancer Netw. 7:1060–1096.
2009. View Article : Google Scholar
|
|
3
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:pp.
8418–8423. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Panel members: Thresholds for
therapies: Highlights of the St Gallen international expert
consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implicatios. Proc Natl
Acad Sci USA. 98:pp. 10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE,
Green AR, Ellis IO, et al: MicroRNA expression profiling of human
breast cancer identifies new markers of tumor subtype. Genome Biol.
8:R2142007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang M, Mo J, Huang P, et al:
Clinicopathologic profiles of breast cancer in young women: A
report of 85 cases. Chinese Journal of General Surgery. 23:665–669.
2014.
|
|
9
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Onitilo AA, Engel JM, Greenlee RT and
Mukesh BN: Breast cancer subtypes based on ER/PR and Her2
expression: Comparison of clinicopathologic features and survival.
Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buzdar AU, Ibrahim NK, Francis D, Booser
DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano
SH, et al: Significantly higher pathologic complete remission rate
after neoadjuvant therapy with trastuzumab, paclitaxel, and
epirubicin chemotherapy: Results of a randomized trial in human
epidermal growth factor receptor 2-positive operable breast cancer.
J Clin Oncol. 23:3676–3685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lund MJ, Butler EN, Bumpers HL, Okoli J,
Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM and
Gabram SG: High prevalence of triple-negative tumors in an urban
cancer center. Cancer. 113:608–615. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carrio M, Arderiu G, Myers C and Boudreau
NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells
in a three-dimensional culture model. Cancer Res. 65:7177–7185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grøndahl-Hansen J, Christensen IJ, Briand
P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K and Brünner N:
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts
predicts prognosis in low-risk breast cancer patients. Clin Cancer
Res. 3:233–239. 1997.PubMed/NCBI
|
|
15
|
Lowery AJ, Miller N, Devaney A, McNeill
RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and
Kerin MJ: MicroRNA signatures predict oestrogen receptor,
progesterone receptor and HER-2/neu receptor status in breast
cancer. Breast Cancer Res. 11:R272009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Zhu J, Cao H, Ren H and Fang X:
miR-10b promotes cell invasion through RhoC-AKT signaling pathway
by targeting HOXD10 in gastric cancer. Int J Oncol. 40:1553–1560.
2012.PubMed/NCBI
|
|
17
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ujifuku K, Mitsutake N, Takakura S,
Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K,
Nagata I and Yamashita S: miR-195, miR-455-3p and miR-l0a(*) are
implicated in acquired temozolomide resistance in glioblastoma
multiforme cells. Cancer lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Biagioni F, Bossel Ben-Moshe N, Fontemaggi
G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni
S, De Angelis F, et al: miR-10b*, a master inhibitor of the cell
cycle, is down-regulated in human breast tumours. EMBO Mol Med.
4:1214–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Wen J, Tang J, Lai M and Bu H:
Breast Cancer Pathology. Eighth. People's Medical Publishing House
(China); pp. 373–377. 2005
|
|
21
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American society of clinical oncology/college of American
pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. Arch Pathol Lab Med.
131:18–43. 2007.PubMed/NCBI
|
|
22
|
Prisack HB, Karreman C, Modlich O,
Audretsch W, Danae M, Rezai M and Bojar H: Predictive biological
markers for response of invasive breast cancer to
anthracycline/cyclophos-phamide-based Primary (radio-)chemotherapy.
Anticancer Res. 25:4615–4621. 2005.PubMed/NCBI
|
|
23
|
Yarden Y: Biology of HER2 and its
importance in breast cancer. Oncology. 61 Suppl:S1–S13. 2001.
View Article : Google Scholar
|
|
24
|
Stewart BW and Wild CP: World cancer
report 2014. Int Age Res Can. 28:17–27. 2014.
|
|
25
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB,
Zhou ZM and Guan ZZ: Clinical characteristics and prognosis of
different subtypes of breast cancer. Zhonghua Zhong Liu Za Zhi.
30:456–461. 2008.(In Chinese). PubMed/NCBI
|
|
27
|
Prat A and Perou C: Deconstructing the
molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
iddex, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J and Wu JH: The clinical value of
endocrine therapy for breast cancer in elderly women. J Can Cont
Treat. 23:3852010.
|
|
30
|
Durbecq V, Ameye L, Veys I, Paesmans M,
Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM,
Piccart M and Larsimont D: A significant proportion of elderly
patients develop hormone-dependant ‘luminal-B’ tumours associated
with aggressive characteristics. Crit Rev Oncol Hematol. 67:80–92.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Onitilo AA, Engel JM, Greenlee RT and
Mukesh BN: Breast cancer subtypes based on ER/PR and Her2
expression: Comparison of clinicopathologic features and survival.
Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gee HE, Camps C, Buffa FM, Colella S,
Sheldon H, Gleadle JM, Ragoussis J and Harris AL: MicroRNA-10b and
breast cancer metastasis. Nature. 455:E8–E9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Green S, Walter P, Kumar V, Krust A,
Bornert JM, Argos P and Chambon P: Human oestrogen receptor cDNA:
Sequence, expression and homology to v-erb-A. Nature. 320:134–139.
1986. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Durbecq V, Ameye L, Veys I, Paesmans M,
Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM,
Piccart M and Larsimont D: A significant proportion of elderly
patients develop hormone-dependant ‘luminal-B’ tumours associated
with aggressive characterristics. Crit Rev Oncol Hematol. 67:80–92.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Winer EP, Hudis C, Burstein HJ, Wolff AC,
Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J,
et al: American Society of Clinical Oncology technology assessment
on the use of aromatase inhibitors as adjuvant therapy for
postmenopausal women with hormone receptor-positive breast cancer:
Status report 2004. J clin Oncol. 23:619–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartlett JM, Ellis IO, Dowsett M, Mallon
EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM,
et al: Human epidermal growth factor receptor 2 status correlates
with lymph node involvement in patients with estrogen receptor (ER)
negative, but with grade in those with ER-positive early-stage
breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol.
25:4423–4430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Q, Chen J, Li HJ, Yu M, Tian CX and
Lü Q: Clinical features and prognosis analysis of different breast
cancer molecular subtypes. Zhonghua Zhong Liu Za Zhi. 33:42–46.
2011.(In Chinese). PubMed/NCBI
|
